

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior listings of claims:

- 1.-15. (Cancelled)
16. (New) A method to treat or prevent cancer comprising administering to an individual a cross-linking agent capable of cross-linking at least two molecules of the protein tyrosine phosphatase Sap-1.
17. (New) The method of claim 16, wherein the cancer is a src-associated cancer.
18. (New) The method of claim 16, wherein the cancer is a gastrointestinal cancer.
19. (New) The method of claim 18, wherein the gastrointestinal cancer is selected from the group consisting of esophageal tumor, stomach cancer, small-bowel tumor, large-bowel tumor, and pancreatic cancer.
20. (New) The method of claim 16, wherein the cross-linking agent is a proteinaceous cross-linker.
21. (New) The method of claim 20, wherein the proteinaceous cross-linker is an antibody directed against the extra-cellular domain of Sap-1.
22. (New) The method of claim 21, wherein the antibody is directed against a Fibronectin-type III like domain of Sap-1.
23. (New) The method of claims 20, wherein the cross-linking agent is a monoclonal antibody.
24. (New) The method of claims 21, wherein the cross-linking agent is a monoclonal antibody.

25. (New) The method of claim 20, wherein the cross-linking agent is a humanized antibody.
26. (New) The method of claims 21, wherein the cross-linking agent is a humanized antibody.
27. (New) The method of claim 20, wherein the cross-linking agent is a human antibody.
28. (New) The method of claims 21, wherein the cross-linking agent is a human antibody.
29. (New) The method of claim 20, wherein the cross-linking agent is a soluble fragment of the extracellular domain of Sap-1.
30. (New) The method of claim 20, wherein the cross-linking agent comprises one, two, three, four, five, six, seven or eight Fibronectin-type III like repeats of Sap-1.
31. (New) The method of claim 20, wherein the cross-linking agent is selected from the group consisting of: a mutein of the proteinaceous cross-linking agent, a fused protein of the proteinaceous cross-linking agent, a functional derivative of the proteinaceous cross-linking agent, an active fraction of the proteinaceous cross-linking agent, and salt of the proteinaceous cross-linking agent.
32. (New) The method of claim 20, wherein the cross-linking agent is a functional derivative of the proteinaceous cross-linking agent comprising at least one moiety attached to one or more functional groups, which occur as one or more side chains on the amino acid residues.
33. (New) The method of claim 32, wherein the moiety is a polyethylene moiety.